Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women

Journal of Women's Health

Volumn 21, Issue 4, 2012, Pages 379-387

  Rivera, Cathleen M ^a   Song, Juhee ^a   Copeland, Laurel ^a   Buirge, Chris ^b   Ory, Marcia ^c   McNeal, Catherine J ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b Navigant Healthcare Department   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG USE; FAMILY HISTORY; FEMALE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SELF REPORT; UNITED STATES;

ADULT; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; ODDS RATIO; PHYSICIAN-PATIENT RELATIONS; RISK ASSESSMENT; UNITED STATES;

EID: 84859793751     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2011.2990     Document Type: Review

References (27)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010;121:e46-e215.
2. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol 2007;49:1230-1250. (Pubitemid 46400344)
3. Steering Committee of the Physician's Health Study Research Group. Final report on the aspirin component of the ongoing physician's health study. N Engl J Med 1989;321: 129-135.
4. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762. (Pubitemid 28269185)
5. Thrombosis prevention trial: Randomized trial of lowintensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351:233-241.
6. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomized trial in general practice. Lancet 2001;357: 89-95.
7. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.
8. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009;373:1849-1860.
9. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: An update of evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150: 405-410.
10. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes. Ann Intern Med 1996;124:292-298. (Pubitemid 26047454)
11. Shahar E, Folsom AR, Romm FJ, et al. Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1996;131:915-922. (Pubitemid 26135754)
12. Stafford RS. Apsirin use is low among United States outpatients with coronary artery disease. Circulation 2000;101: 1097-1101. (Pubitemid 30146609)
13. Hassan M, Amonkar M. Aspirin use for primary and secondary prophylaxis of cardiovascular disease. Curr Ther Res 2001;62:676-690. (Pubitemid 33097452)
14. Cheng EM, Cohen SN, Lee ML, Vassar SD, Chen AY. Use of antithrombotic agents among US stroke survivors, 2000- 2006. Am J Prev Med 2010;38:47-53.
15. Kim C, Beckles GL. Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am J Prev Med 2004;27:1-7. (Pubitemid 38813177)
16. Cannon CP, Rhee KE, Califf RM, et al. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the Reduction of Atherosclerosis for Continued Health [REACH] registry). Am J Cardiol 2010;105:445-452.
17. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-2572. (Pubitemid 37430158)
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
19. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006;30:74-77. (Pubitemid 43083548)
20. Soni A. Aspirin use among the adult U.S. noninstitutionalized population, with and without indicators of heart disease, 2005. Medical Expenditure Panel Survey (MEPS) Statistical Brief #179. Agency for Healthcare Research and Quality, 2007.
21. Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes 2010;3: 120-127.
22. Mosca L, Jones WK, King KB, Ouyang P, Redberg FR, Hill MN. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. Arch Fam Med 2000;9:506-515.
23. Stafford RS, Blumenthal D. Specialty differences in cardiovascular disease prevention practices. J Am Coll Cardiol 1998;32:1238-1243. (Pubitemid 28531944)
24. Cook NR, Chae CU, Mueller FB, et al. Mis-medication and underutilization of aspirin in the prevention and treatment of cardiovascular disease. MedGenMed [serial online] 1999;1. Available at www.medscape.com/viewarticle/ 408025
25. Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: Factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.
26. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008;300:2134-2141.
27. Levenson JW, Skerrett PJ, Gaziano JM. Reducing the global burden of cardiovascular disease: The role of risk factors. Prev Cardiol 2002;5:188-199.(Pubitemid 35283512)